6 research outputs found

    Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    Get PDF

    C-reactive Protein: Adjunct to Cardiovascular Risk Assessment

    No full text
    ABSTRACT Objectives: The study aimed to investigate whether elevated plasma high sensitivity C-reactive protein (hs-CRP) levels are independently associated with an increased risk of cardiovascular disease (CVD) and to then assess the effectiveness of the addition of hs-CRP testing to cardiovascular risk assessment by standard lipid screening. Methods: A retrospective hospital-based case-control study was designed. All patients attending Cross Crossing Medical Centre (CCMC) for routine cardiovascular assessment or emergency treatment were included. Cases were defined as patients with a cardiovascular event and controls as those without an event. Data collected included blood measurements of hs-CRP and cholesterol, demographic data, drug and risk factor history. Results: Odds ratio of 1.84 (95% CI 1.00, 3.38) indicated that a patient with elevated hs-CRP is 1.84 times more at risk of CVD than one with normal hs-CRP. Additionally, the association between hs-CRP and CVD was found to be independent of the other risk factors (p = 0.058). Hs-CRP ranked fourth as an indicator of risk above smoking and diabetes, and patients with both high hs-CRP and high cholesterol (OR = 9.5) were 3.5 times more at risk of CVD than someone with high cholesterol alone (OR = 6.0). Conclusions: Hs-CRP testing enhanced the clinical identification of patients at risk of cardiovascular events. It can therefore contribute to timely implementation of effective lifestyle modification and pharmaceutical intervention. Prote铆na C reactiva: Complemento para la Evaluaci贸n del Riesgo Cardiovascular RESUMEN Objetivos: El estudio apunt贸 a investigar si los niveles de prote铆na C reactiva (PCR-hs) de alta sensibilidad de plasma elevado est谩n independientemente asociados con el aumento del riesgo de la enfermedad cardiovascular (ECV), y luego evaluar la efectividad de a帽adir la prueba PCR-hs para la evaluaci贸n del riesgo cardiovascular mediante detecci贸n (screening) est谩ndar de l铆pidos. M茅todos: Se dise帽贸 un estudio caso-control retrospectivo con sede en el hospital. En el mismo fueron incluidos todos los pacientes que asist铆an al Centro M茅dico Cross Crossing (CCMC) para una evaluaci贸n cardiovascular de rutina o para tratamiento de urgencia. Los casos fueron definidos como pacientes con controles y eventos cardiovasculares, o sin un evento. Los datos recogidos incluyeron mediciones sangu铆neas de PRC-hs y colesterol, datos demogr谩ficos, historia de factores de riesgo y de drogas. Resultados: El odds ratio de 1.84 (95% CI 1.00, 3.38) indic贸 que un paciente con PCR-hs elevado tiene un riesgo de ECV 1.84 veces mayor que uno con PCR-hs normal. Adem谩s, se hall贸 que la asociaci贸n entre el PCR-hs y la ECV era independiente de los otros factores de riesgo (p = 0.058). La PCR-hs alcanz贸 el cuarto lugar como indicador de riesgo, por encima del h谩bito de fumar y la diabetes, y los pacientes con alto PCR-hs y alto colesterol (OR = 9.5) presentaban riesgo de ECV 3.5 veces mayor que aquellos que s贸lo ten铆an colesterol alto (OR = 6.0). Conclusiones: Las pruebas de PCR-hs mejoraron la identificaci贸n cl铆nica de pacientes con riesgo de eventos cardiovasculares. Por lo tanto, estas pruebas pueden contribuir a implementar oportunamente una modificaci贸n para un estilo de vida y una intervenci贸n farmac茅utica que sean efectivos
    corecore